Robert Null, M.D., a board-certified retina specialist at Discover Vision Centers, says that it’s not a rare case that patients come looking for an ophthalmologist in Independence because someone hears “glaucoma suspect” and realizes that waiting for symptoms is not a strategy. It also starts to feel personal when family history enters the picture, because the National Eye Institute lists family history as a glaucoma risk factor and notes that early symptoms are often none. [1]
A quiet disease needs a plan you can actually repeat and keep.
The “silent thief” problem (and what actually prevents it)
Glaucoma often has no early symptoms. The National Eye Institute says the symptoms can start so slowly that you may not notice them, and that the only way to find out if you have glaucoma is to get a comprehensive dilated eye exam. It also states that there is no cure, but that early treatment can often stop the damage and protect vision. [1]
A quiet disease deserves a loud plan.
Baseline testing turns worry into data
Baselines matter because they create the starting point for future decisions. The National Eye Institute lists diagnosis with a dilated eye exam and visual field testing, while a peer-reviewed review explains that early detection and monitoring are critical in glaucoma and that OCT helps detect and monitor structural glaucomatous damage.
Baselines turn fear into data, and data protects decisions.
Macular OCT and visual fields tell a clearer story together
Ophthalmology Times reports that macular OCT has become “nearly indispensable” in glaucoma clinical practice. [2]
The same article notes that current OCT devices show high levels of structure/function correlation in glaucoma, while the review by Geevarghese and colleagues explains that OCT supports detection and monitoring of structural damage in a disease that causes irreversible blindness.
In practice, that is why clinicians pair structure and function: structure shows what is changing, and function shows what it is costing.
Treatments that match the stage, not the panic
Glaucoma treatment is built around lowering intraocular pressure. The National Eye Institute lists medicine, usually eye drops, laser treatment, and surgery as treatment options, and the adherence review notes that lowering pressure is the evidence-based way to stop or slow progression for many glaucoma types. [1][4]
The right plan is not the most dramatic one. It is the one that fits the stage of the disease and the person who has to live with it.
Follow-up is treatment (and why it’s easy to miss)
Follow-up is not an extra step in glaucoma care. It is part of the treatment itself because monitoring is how clinicians tell whether pressure control, structural change, and visual function are staying stable over time. [1][3]
The adherence review also describes practical ways to improve consistency, including automated reminders, instillation aids, better communication and education, and better tolerability of eye-drop formulations. [4]
Follow-up is treatment because monitoring is how glaucoma care works.
Medication routines that real people can keep
Medication routines work best when they are designed instead of merely hoped for. The review by Tapply and Broadway found that adherence to anti-glaucoma therapy is often low and that communication, reminders, and tolerable formulations can improve persistence more effectively than vague encouragement alone. [4]
The best medication plan is the one you can actually follow.
The next step that protects independence
Glaucoma protects independence through consistency, not through waiting. A strong next step is a baseline exam, clear testing, and a follow-up schedule you can keep. When the disease is quiet, your plan has to do the talking. [1][3][4]
- National Eye Institute, “Glaucoma,” November 26, 2025.
- Lynda Charters, “Macular OCT: A must for treating glaucoma patients,” March 2026.
- Alexi Geevarghese, Gadi Wollstein, Hiroshi Ishikawa, and Joel S. Schuman, “Optical Coherence Tomography and Glaucoma,” September 15, 2021.
- Ian Tapply and David C. Broadway, “Improving Adherence to Topical Medication in Patients with Glaucoma,” July 2, 2021.
